UK consults on value based pricing system
This article was originally published in SRA
Executive Summary
The UK department of health has released for consultation its plans for introducing a value-based pricing system to determine how much it will pay for new medicines1,2. The plan focuses on determining maximum prices or thresholds for medicines that will reflect the different values that different treatments offer. The proposals also touch on the role that the National Institute for health and Clinical Excellence will play3,4.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.